Pharmacological treatment of Parkinson’s disease: life beyond dopamine D2/D3 receptors?
✍ Scribed by G. Linazasoro; N. Van Blercom; L. Ugedo; J. A. Ruiz Ortega
- Publisher
- Springer
- Year
- 2008
- Tongue
- English
- Weight
- 156 KB
- Volume
- 115
- Category
- Article
- ISSN
- 1435-1463
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
We read with interest the article by Grevle and colleagues, 1 reporting in Norway an association between the variant allele A1 of the TaqI A restriction fragment length polymorphism (RFLP) located in the dopamine D2 receptor (DRD2) gene and Parkinson's disease (PD). Similar findings have been report
## Abstract Novelty seeking is a temperament trait characterized by impulsiveness and exploratory behavior. Dopamine has been suggested to be the primary neurotransmitter modulator of novelty seeking, and in young healthy subjects, a correlation between increased novelty seeking and decreased insul
## Abstract In a case control study, we examined the association of DRD2 Taq1A and Taq1B polymorphisms and risk of PD, and evaluated the strength of linkage disequilibrium of the polymorphisms. The Taq1A and Taq1B polymorphisms were in strong linkage disequilibrium. There was, however, no significa